Gland Pharma Ltd
NSE:GLAND

Watchlist Manager
Gland Pharma Ltd Logo
Gland Pharma Ltd
NSE:GLAND
Watchlist
Price: 1 755.05 INR -1.79% Market Closed
Market Cap: 289.1B INR
Have any thoughts about
Gland Pharma Ltd?
Write Note

Intrinsic Value

The intrinsic value of one GLAND stock under the Base Case scenario is 1 457.5 INR. Compared to the current market price of 1 755.05 INR, Gland Pharma Ltd is Overvalued by 17%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GLAND Intrinsic Value
1 457.5 INR
Overvaluation 17%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Gland Pharma Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for GLAND cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about GLAND?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Gland Pharma Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Gland Pharma Ltd

Provide an overview of the primary business activities
of Gland Pharma Ltd.

What unique competitive advantages
does Gland Pharma Ltd hold over its rivals?

What risks and challenges
does Gland Pharma Ltd face in the near future?

Has there been any significant insider trading activity
in Gland Pharma Ltd recently?

Summarize the latest earnings call
of Gland Pharma Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Gland Pharma Ltd.

Provide P/S
for Gland Pharma Ltd.

Provide P/E
for Gland Pharma Ltd.

Provide P/OCF
for Gland Pharma Ltd.

Provide P/FCFE
for Gland Pharma Ltd.

Provide P/B
for Gland Pharma Ltd.

Provide EV/S
for Gland Pharma Ltd.

Provide EV/GP
for Gland Pharma Ltd.

Provide EV/EBITDA
for Gland Pharma Ltd.

Provide EV/EBIT
for Gland Pharma Ltd.

Provide EV/OCF
for Gland Pharma Ltd.

Provide EV/FCFF
for Gland Pharma Ltd.

Provide EV/IC
for Gland Pharma Ltd.

Show me price targets
for Gland Pharma Ltd made by professional analysts.

What are the Revenue projections
for Gland Pharma Ltd?

How accurate were the past Revenue estimates
for Gland Pharma Ltd?

What are the Net Income projections
for Gland Pharma Ltd?

How accurate were the past Net Income estimates
for Gland Pharma Ltd?

What are the EPS projections
for Gland Pharma Ltd?

How accurate were the past EPS estimates
for Gland Pharma Ltd?

What are the EBIT projections
for Gland Pharma Ltd?

How accurate were the past EBIT estimates
for Gland Pharma Ltd?

Compare the revenue forecasts
for Gland Pharma Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Gland Pharma Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Gland Pharma Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Gland Pharma Ltd compared to its peers.

Compare the P/E ratios
of Gland Pharma Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Gland Pharma Ltd with its peers.

Analyze the financial leverage
of Gland Pharma Ltd compared to its main competitors.

Show all profitability ratios
for Gland Pharma Ltd.

Provide ROE
for Gland Pharma Ltd.

Provide ROA
for Gland Pharma Ltd.

Provide ROIC
for Gland Pharma Ltd.

Provide ROCE
for Gland Pharma Ltd.

Provide Gross Margin
for Gland Pharma Ltd.

Provide Operating Margin
for Gland Pharma Ltd.

Provide Net Margin
for Gland Pharma Ltd.

Provide FCF Margin
for Gland Pharma Ltd.

Show all solvency ratios
for Gland Pharma Ltd.

Provide D/E Ratio
for Gland Pharma Ltd.

Provide D/A Ratio
for Gland Pharma Ltd.

Provide Interest Coverage Ratio
for Gland Pharma Ltd.

Provide Altman Z-Score Ratio
for Gland Pharma Ltd.

Provide Quick Ratio
for Gland Pharma Ltd.

Provide Current Ratio
for Gland Pharma Ltd.

Provide Cash Ratio
for Gland Pharma Ltd.

What is the historical Revenue growth
over the last 5 years for Gland Pharma Ltd?

What is the historical Net Income growth
over the last 5 years for Gland Pharma Ltd?

What is the current Free Cash Flow
of Gland Pharma Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Gland Pharma Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Gland Pharma Ltd

Current Assets 64B
Cash & Short-Term Investments 29.3B
Receivables 14.9B
Other Current Assets 19.8B
Non-Current Assets 44.6B
PP&E 39.3B
Intangibles 3.7B
Other Non-Current Assets 1.6B
Current Liabilities 15.4B
Accounts Payable 10B
Other Current Liabilities 5.4B
Non-Current Liabilities 5.4B
Long-Term Debt 1.3B
Other Non-Current Liabilities 4.1B
Efficiency

Earnings Waterfall
Gland Pharma Ltd

Revenue
58.9B INR
Cost of Revenue
-23.4B INR
Gross Profit
35.5B INR
Operating Expenses
-26.6B INR
Operating Income
8.9B INR
Other Expenses
-2B INR
Net Income
6.9B INR

Free Cash Flow Analysis
Gland Pharma Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q2 FY '25, Gland Pharma reported revenues of INR 14,058 million, a 2% increase year-over-year, driven by a 5% rise in the U.S. market. However, Cenexi faced a 5% revenue decline due to a scheduled shutdown. The consolidated EBITDA stood at INR 2,961 million with a margin of 21%. Notably, Gland's base business achieved a solid 34% EBITDA margin. The company aims for a positive EBITDA from Cenexi by Q4 2025, anticipating revenues to exceed EUR 200 million in the upcoming fiscal year. Despite a net profit dip of 16%, Gland remains optimistic, citing healthy cash flow and ongoing investments in R&D and new capacities.

What is Earnings Call?
Fundamental Scores

GLAND Profitability Score
Profitability Due Diligence

Gland Pharma Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Year Average ROIC
Positive Free Cash Flow
Positive Operating Income
59/100
Profitability
Score

Gland Pharma Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

GLAND Solvency Score
Solvency Due Diligence

Gland Pharma Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Gland Pharma Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GLAND Price Targets Summary
Gland Pharma Ltd

Wall Street analysts forecast GLAND stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GLAND is 1 756.35 INR with a low forecast of 1 226.14 INR and a high forecast of 2 257.5 INR.

Lowest
Price Target
1 226.14 INR
30% Downside
Average
Price Target
1 756.35 INR
0% Upside
Highest
Price Target
2 257.5 INR
29% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for GLAND?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for GLAND is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

GLAND Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Gland Pharma Ltd Logo
Gland Pharma Ltd

Country

India

Industry

Pharmaceuticals

Market Cap

289.1B INR

Dividend Yield

1.14%

Description

Gland Pharma Ltd. manufactures pharmaceutical ingredients and injectable formulations. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2020-11-20. The firm provides a range of injectables including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions and ophthalmic solutions. The company provides contract development and manufacturing services, such as evaluation of development needs, identifying application program interface (API) sources, analytical method development, formulation development and product/technology know-how; and manufacturing of registration batches, studies, dossier compilation for regulatory submission and commercial production. The Company’s therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Blood Related, Cardiac, Gastrointestinal, Gynaecological, Hormones, Neuro / Cns Ophthal / Otologicals, Pain/Analgesics, Respiratory and Vitamins / Minerals / Nutrients.

Contact

TELANGANA
Hyderabad
Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads, D.P. Pally, Dundigal Gandimaisamma Mandal Medchal-Malkajgiri District
+914030510999
www.glandpharma.com

IPO

2020-11-20

Employees

3 961

Officers

CEO & Executive Chairman
Mr. Srinivas Sadu
Chief Financial Officer
Mr. Ravi Shekhar Mitra
Company Secretary & Vice-President of Compliance & CSR
Mr. Sampath Kumar Pallerlamudi
Chief Operating Officer
Mr. Satnam Singh Loomba
Head of Investments, Strategy & Investor Relations
Mr. Ankit Gupta
Head of Domestic Marketing
Mr. Surinder Koul
Show More
Senior Vice President of R&D
Dr. Surapanini Sridevi
Head of Quality
Mr. K Raghuramachandra Rao
Chief Financial Controller
Mr. Rong Wu
Show Less

See Also

Discover More
What is the Intrinsic Value of one GLAND stock?

The intrinsic value of one GLAND stock under the Base Case scenario is 1 457.5 INR.

Is GLAND stock undervalued or overvalued?

Compared to the current market price of 1 755.05 INR, Gland Pharma Ltd is Overvalued by 17%.

Back to Top